Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for OpeningGlobeNewsWire • 08/08/23
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow StatementGlobeNewsWire • 07/28/23
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid ArthritisGlobeNewsWire • 07/26/23
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep ApnoeaGlobeNewsWire • 07/21/23
Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep ApnoeaGlobeNewsWire • 07/18/23
Incannex Announces Intention to Redomicile to United States, List all Shares on NasdaqGlobeNewsWire • 07/10/23
Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company's Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA')GlobeNewsWire • 07/06/23
Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023GlobeNewsWire • 06/23/23
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical TrialGlobeNewsWire • 06/16/23
World Renowned International Psychedelics Experts Join Clarion Clinics Advisory BoardGlobeNewsWire • 05/30/23
Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary CompanyGlobeNewsWire • 05/16/23
Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675AGlobeNewsWire • 05/03/23
Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675AGlobeNewsWire • 05/02/23
Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EUGlobeNewsWire • 04/14/23
Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic ExpertsGlobeNewsWire • 03/16/23
Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatmentGlobeNewsWire • 03/15/23
Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial UseGlobeNewsWire • 03/03/23
Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid ArthritisGlobeNewsWire • 02/28/23
Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin DiseasesGlobeNewsWire • 11/29/22
Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-OGlobeNewsWire • 11/28/22
Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow StatementGlobeNewsWire • 10/28/22
Incannex Completes Dosing in Phase 1 Clinical Trial to Assess Multi-Use, Anti-Inflammatory Drug IHL-675A; Proceeds to Phase 2 Clinical TrialsGlobeNewsWire • 10/13/22